BIOMAT Database Logo BIOMAT Database Logo

Budesonide in inflammatory bowel disease. 1996

C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Department of Gastroenterology-Hepatology, University Hospital Leiden, Netherlands.

Due to its immunomodulatory and anti-inflammatory properties glucocorticosteroids have proved to be highly efficacious in patients with inflammatory bowel disease. However, because of the risk of side-effects, the dose and duration of therapy with systemically acting glucocorticosteroids have to be restricted. Recently the use of topically acting glucocorticosteroids has attracted great interest. Among the various topically acting glucocorticosteroids budesonide has emerged as the most promising. Budesonide is highly potent, is readily water-soluble and has low systemic bioavailability, thus reducing the risk of corticosteroid-related side-effects. When given as enema to patients with proctitis or proctosigmoiditis, the efficacy of budesonide is greater than that of placebo and equal to that of prednisolone or 5-aminosalicylic acid enemas. In an enteric-coated formulation budesonide is more effective than placebo in achieving and maintaining remission in patients with ileocecal Crohn's disease. Although corticosteroid-related side-effects are rare, some suppression of the hypothalamic-pituitary-adrenal axis may occur.

UI MeSH Term Description Entries
D011282 Pregnenediones Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. Diketopregnenes,Dioxopregnenes
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004733 Enema Insertion of a solution or compound through the RECTUM with the purpose of cleansing the COLON or for diagnostic procedures. Enemata,Enemas,Enematas
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents

Related Publications

C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
[Budesonide and inflammatory bowel disease].
December 1999, Gastroenterologia y hepatologia,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Budesonide in the treatment of inflammatory bowel disease.
July 2011, Expert review of clinical immunology,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
[Budesonide in inflammatory bowel disease: a meta-analysis].
January 2001, Medicina clinica,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Budesonide for inflammatory bowel disease. Is it a magic bullet?
September 1994, The New England journal of medicine,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
[Budesonide for chronic inflammatory bowel diseases].
October 1998, Deutsche medizinische Wochenschrift (1946),
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
September 1994, The New England journal of medicine,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Oral formulations of budesonide: a novel treatment for inflammatory bowel disease.
November 2008, Drugs of today (Barcelona, Spain : 1998),
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease.
January 2013, American journal of veterinary research,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX.
December 2018, Scandinavian journal of gastroenterology,
C B Lamers, and M J Wagtmans, and A van der Sluys Veer, and R A van Hogezand, and G Griffioen
Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
December 2018, Biomaterials,
Copied contents to your clipboard!